Adamas Pharmaceuticals Return on Equity

Adamas Pharmaceuticals (ADMS) currently reports a ROE of 290.23%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore Adamas Pharmaceuticals's ROE history and peer comparisons.

Adamas Pharmaceuticals's ROE of 290.23% is higher than the Healthcare sector average of -100.59%. That is roughly 388.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Adamas Pharmaceuticals's current 290.23% should be judged against Healthcare norms (sector average: -100.59%) and against ADMS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 290.23%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Adamas Pharmaceuticals, and consider following ADMS for alerts when major investors trade the stock.

Adamas Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 290.23% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ADMS with unrelated industries.